Weill Cornell Leukemia Program

Home
United States
New York, NY
Weill Cornell Leukemia Program

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Weill Cornell Leukemia Program, Hospital, 520 East 70th Street, Starr Pavilion, 3rd Floor, New York, NY.

The Leukemia Program provides:

--A multidisciplinary team with specialists in infectious diseases, geriatrics, gastroenterology, cardiology, nephrology, neurology, pulmonary and critical care medicine, psychiatry, social work, nutrition and others

--Emphasis on highly personalized, individual care

--Close collaboration with comprehensive bone marrow and stem cell transplantation program

--Access to cutting edge clinical trials involving newly developed drugs, biological therapies and antibodies

--Specialized in-patient and out-patient units with highly trained staff and ancillary professionals experienced with the specific needs of these patients

--Extensive collaborations with world-renowned translational scientists, specific expertise in leukemia stem cells, genomics, epigenetics

--Specialized focus on development of clinical trials targeting leukemia stem cells, both at the time of diagnosis as well as trying to target and eradicate left-over leukemia stem cells in patients already in remission. The Leukemia Fighters Fund accepts charitable donations which are completely and specifically for leukemia research at Weill Cornell, has already provided funds for new recruits, novel treatment protocols, equipment and other critical needs

06/26/2025

At , Dr. Gail Roboz presented results from evaluating a combination therapy regimen for acute myeloid ( ) which showed encouraging survival outcomes:
https://bit.ly/44iDUPE

04/21/2025

Our Weill Cornell Medicine/NewYork-Presbyterian Hospital team is dedicated to raising awareness for acute myeloid leukemia ( ). On , we share our support and commitment to caring for patients and all those caregivers and loved ones impacted by this type of .

Know AML

11/07/2024

Dr. Pinkal Desai discussed treatment approaches for acute myeloid ( ) patients who are ineligible for with VJHemOnc at :

Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, notes that for patients with acute myeloid leukemia (AML) who...

11/04/2024

From : Dr. Pinkal Desai discussed the complexities of secondary acute myeloid ( ), including differences between therapy-related and AML that transforms from other malignancies

Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the complexities of secondary acute myeloid leukemia (AML), distinguishing...

11/01/2024

WATCH: Dr. Pinkal Desai spoke about the challenges of treating secondary acute myeloid ( ) with standard therapies

Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.

10/30/2024

Dr. Pinkal Desai led that found clonal hematopoiesis of indeterminate potential (CHIP) & mosaic chromosomal alterations (mCAs) are associated with increased risk of . CHIP is also linked with higher mortality risk

08/23/2024

Watch Dr. Gail Roboz explain what patients with acute myeloid ( ) need to know about test results in this Patient Empowerment Network video:

Dr. Gail Roboz discusses collaboration with the healthcare team to interpret test results and questions to ask during the discussion.

08/21/2024

In another Patient Empowerment Network video, Dr. Gail Roboz speaks about inhibitor therapies for acute myeloid ( ):

Dr. Gail Roboz explains inhibitor therapies, their targets, the patient type they may benefit most, and a new class of targeted treatments.

08/19/2024

What are the treatment options and phases of therapy for acute myeloid ( )? Dr. Gail Roboz outlines the options via Patient Empowerment Network:

Dr. Roboz discusses available therapies to treat AML and maintain remission, the timing of these therapies, and novel treatment approaches.

08/15/2024

WATCH: Dr. Gail Roboz discusses the types of tests that occur after an acute myeloid ( ) diagnosis in part 3 of her video series with Patient Empowerment Network

Dr. Gail Roboz explains procedures and tests to confirm an AML diagnosis, disease risk, genetic markers, and developing a treatment plan.

08/12/2024

In part 2 of Dr. Gail Roboz’s video series with Patient Empowerment Network, learn more about how acute myeloma ( ) treatment decisions are made:

Dr. Gail Roboz explains the collaborative decision-making process between patients and clinicians when exploring treatment options.

08/09/2024

Dr. Gail Roboz joined Patient Empowerment Network for a video series on acute myeloid ( ) treatments and treatment decisions. In the first video, she breaks down the importance of patients advocating for themselves with their care team:

Dr. Roboz discusses the importance of participating in AML treatment and care, factors that impact options, and self-advocacy advice

Address

520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY
10021

Telephone

+16469622700

Website

https://weillcornell.org/leukemia

Alerts

Be the first to know and let us send you an email when Weill Cornell Leukemia Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Magnus Wellness
16 E 40th Street, Fl 4

Want your practice to be the top-listed Clinic in New York?

Our Story

The Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital is comprised of an internationally recognized team of physicians and scientists who specialize in the treatment of acute and chronic leukemias including, but not limited to, acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and bone marrow failure diseases such as aplastic anemia, paroxysmal nocturnal hemoglobinuria, large granular lymphocytic leukemia, and others.

Led by Gail J. Roboz, MD, our team is at the forefront of breakthrough biomedical and clinical research in leukemia. We have participated in the development of all major drugs recently approved by the United States Food and Drug Administration (FDA) for patients with leukemia. Patients in our Program have access to a robust clinical trials portfolio that includes studies for newly diagnosed, as well as relapsed/refractory adult patients.

Every second counts in the fight against leukemia, a disease that can manifest in highly aggressive and fast-growing forms. As part of our dedication to addressing treatment needs as quickly as possible, our team of experts is available for same-day appointments for newly diagnosed leukemia patients. To schedule a visit, please call (646) 962-2700.